Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yep how about the AVEO deal? i remember a bogus trial data scandal as well. i did all this DD a long time ago so my memory is not perfect..but the reason i remember the Orlando Health thing was because i believed it was involved somehow .... i don't think it was a coincidence that they decided they didn't want to be connected with MD the same year these other scandals came to light.
do you not remember the DePinho and Chin controversies?
a reminder:
https://cancerletter.com/articles/20170309_1/
i found the MD Anderson Florida connection i was thinking of but it is not a NWBO L site.
https://www.mdanderson.org/newsroom/2013/12/affiliation-between-orlando-health-and-the-university-of-texas-m.html
look for locations link on their website and you will see https://www.mdanderson.org/about-md-anderson/our-locations/texas-medical-center.html
and https://www.mdanderson.org/about-md-anderson/our-locations/katy.html
KATY is at Methodist Hospital
Cherry i remember there were MD anderson sites for L as well. both the U T center in Houston and Methodists are MD Anderson sites and i thought that there was one in FLA as well that is no longer affiliated with MD .. maybe Moffit but not sure
that is very cool.
agree bio this is a takeover defense. those of us who have been invested for three, four and five years are not at all surprised.
it is LP's MO. you are just learning about the Ondra/Woodford affair but the whole scenario was IMO a takeover defense. unfortunately those who were invested at the time paid dearly if they held all the way down. i am not saying it was the right choice by LP at the time, nor now but it is what it is.. same as it ever was.
edit; i believe LP thought at the time and thinks now this is the best way to see this trial to the end with approval.
Yep, right you are.
I agree investor. i also have been reminded by your post as to why i believe RMAT is not likely to apply to A2-73.
from your quote there is the mention of CBER which is different from CDER both regulatory branches but for different drugs...
re·gen·er·ate
verb
1. (of a living organism) regrow (new tissue) to replace lost or injured tissue: "a crab in the process of regenerating a claw"
"Regenerative medicine
From Wikipedia, the free encyclopedia
A colony of human embryonic stem cells
Regenerative medicine is a branch of translational research[1] in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function".[2] This field holds the promise of engineering damaged tissues and organs by stimulating the body's own repair mechanisms to functionally heal previously irreparable tissues or organs.[3]"
the above is how i believe the FDA classifies for RMAT purposes.
On the other hand Mayo Clinic includes rejuvenation;
yep these new guidances are what i was hoping for and maybe what NWBO was waiting on.
Investor i am very excited about what the CNS guidances are going to be. we received great insight into how the FDA is thinking about reforming policies and i am sure we will be very pleased with the new suite of CNS guidances. hey maybe all(most of) the whiners will agree it was worth the wait. :)
it is potentially to be classified a drug not a biological.
regenerative medicine
you know Xena this suite of guidances are specific to cellular and gene therapy ie biologics and RMAT. while these guidelines give us insight into what the CNS suite of guidances could be, these are not those guidances.
i am expecting the suite of CNS guidances will be very positive for Anavex and its shareholders. GL
you are welcome and thank you for the transcript. now him talking about enemies (NMEs) makes sense. HA
got to be careful with these penny stocks..
way to go Reef. i'm just catching up to the old posts. but for my two (or 7) cents on this if anyone reg, beach or any others who have nwbo warrants there are 20k on the bid for 7 cents. if you don't take that unbelievable offer i don't know what to say. if you sold 20k @ .07 you could buy over 8k NWBO. the share price would have to be near $9 by christmas before you start to make money holding warrants versus shares but you have risks of losing it all if the SP is not above $5 before then. JMHO .. GL
Dry eye and fish oil... Mayo Clinic Q & A
https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-q-and-a-fish-oil-supplements-and-dry-eyes/
exactly, right on, do you know Hugh? Hugh dam right.. :)
On the main Anavex board page, right below the quote box and chart.
ok don't believe me, believe your eyes when you read the prospectus..
https://investors.amedica.com/all-sec-filings?page=3#document-1674-0001493152-17-000673
the warrants can be execised at $0.55 . the ".45 warrant" is .45 of a share not $0.45 . so in the offering there were 8 million + shares offered and warrants of .45 shares or about 4 million warrants.
ha ha quite the opposite....
of course you are correct.....
trading on non-public information is illegal.
Oh and that is totally legal right? NOT
yep a lot of very encouraging words for DC VAX and 'small companies' in that statement.
maybe register them as distributed ledger shares at the same time. wouldn't that something?
not the case;
NWBO is incorporated in Delaware...
FYI; technically look for a break above .44 and be aware that there was a big gap down from .63 to .49 which is now begging to be filled.
for good info on fundies read Boston's blog:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135391651
Hi JJ8, I'll give you my opinion on fair market value.
the company just gave us an idea of what value they believe the company was worth in it's distressed state when they 'sold' the assets to the CEO for (IMO) about 10 cents on the dollar for a 2.5 million dollar loan. Market value $25 mil.
so when they (the directors) approved the loan to the (company controlled by) CEO AMDA was in dire straits, ie: in danger of being delisted, encumbered by terms of a loan that severely limited their options and a falling share price. this happened at the beginning of September. I believed at the time this action was necessary.
Now the threat of delisting is diminished and will be negated when corporate governance issues are corrected (SEC filings and R/s to get SP over $1). if /when these issues are are corrected then the IP and other company assets should be valued $75mil to $100mil.
Now the company has a couple of FDA approvals pending and the encumbering loan is to be paid off before the end of year. if/when these happen well your guess is as good as mine as to the market value but i would think many multiples of $100 mil.
GLTY
Reyeton; A 2-73 does not meet the definition. it is not a biologic.
see def. at NIH:
https://www.report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=62
welcome aboard eagle. i like the risk/reward and love the technology. patience is likely to be well rewarded but we are used to being patient right? lol.
GL
excellent post. i have been surprised this topic has not been discussed more on this board. RMAT is a big deal:
https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670.htm
We gobbled that 70k up pretty quick eh? hehe